Filgrastim Products (Neupogen, biosimilars, tbo‑filgrastim) — Coverage Criteria
Customize your policy alerts
Sign up for all quartz policy alerts
Know when quartz releases new policies or updates existing guidance.
Monitor payer policy activity
Guidance on clinical use and prior authorization requirements for filgrastim products (Neupogen and biosimilars, plus tbo-filgrastim) for members of Quartz Health Benefit Plans; specifies indications, dosing durations, and when prior authorization is required.
No material clinical or coverage changes in this revision.
Coverage Criteria for Filgrastim Products
FDA-Approved and Supported Uses
Covered when the FDA-approved indication and any stated prescriber/consultation or patient criteria are met:
chunk 7
chunk 7
chunk 7
chunk 8
chunk 8
chunk 8
chunk 9
Use of filgrastim products is not recommended for clinical circumstances that are not described in the product labeling, NCCN guidelines, or the supporting literature cited in this policy. Indications outside those sources are excluded from recommendation and should not be considered routine uses of filgrastim products.
Situations that lack support in the package labeling, NCCN, or cited literature are explicitly listed as not recommended for use of filgrastim products. Such unsupported uses may be treated as not medically necessary for coverage decisions and could be denied when submitted for benefit review.
Regimens and Dosing Guidance
| Regimen / Indication | Coverage status | Notes (dosing, duration, prescriber/consultation) |
|---|---|---|
| Prophylactic use during myelosuppressive chemotherapy when the chemotherapy regimen has high febrile neutropenia risk (>= 20%). | Covered | Per dosing guidance; prescribe by or in consultation with an oncologist/hematologist as appropriate. Duration and dosing per indication and regimen-specific guidance (see dosing section). |
| Prophylactic use during myelosuppressive chemotherapy when the regimen has intermediate (10%–20%) febrile neutropenia risk and the patient has prescriber-identified additional risk factors for febrile neutropenia. | Covered | Require documentation of patient-specific risk factors; prescribe by or in consultation with an oncologist/hematologist. Duration and dosing per indication (typically up to 6 months; dosing per product guidance). |
Product and Risk Coding
| Neupogen | filgrastim (brand) — Amgen |
| Nivestym | filgrastim-aafi biosimilar — Hospira/Pfizer |
| Zarxio | filgrastim-sndz biosimilar — Sandoz |
| Releuko | filgrastim-ayow biosimilar — Amneal |
| Granix | tbo-filgrastim — Cephalon |
Prior Authorization, Documentation, and Provider Requirements
Prior authorization required for brand Neupogen
Brand Neupogen requires an evaluation of medical necessity; filgrastim biosimilars (Nivestym, Releuko, Zarxio) and tbo‑filgrastim (Granix) do not require prior authorization.
No step therapy algorithm stated
The policy does not specify a step therapy sequence or mandatory trial of alternative filgrastim products prior to coverage.
Required clinical documentation with prescriptions
Prescriptions should document the FDA‑approved indication being treated and, where required by the indication, that the medication was prescribed by or in consultation with an oncologist, hematologist, transplant physician, infectious disease specialist, or other applicable specialist; include relevant risk factors (e.g., chemotherapy regimen FN risk or patient‑specific risk factors).
- Document the specific FDA‑approved indication being treated (see indication-specific durations/dosing).
- Document specialist prescribing or consultation when the indication requires it (oncology/hematology/transplant/infectious disease/radiation expertise as noted).
- Document patient risk factors used to justify prophylactic use (e.g., regimen ≥20% FN risk or prescriber‑identified risk factors).
Medical necessity review for Neupogen (biosimilars/Granix exempt)
Use of BRAND Neupogen requires an evaluation of medical necessity; filgrastim biosimilars and tbo‑filgrastim are exempt from prior authorization per the policy.
Unsupported/off‑label uses may be denied
Uses not supported by package labeling, NCCN, or the cited literature are not recommended and may be considered not medically necessary and denied.
- Do not submit requests for indications outside package labeling, NCCN guidance, or supporting literature without strong supportive evidence.
- Unsupported uses listed as 'not recommended' may be denied as not medically necessary.
Key Definitions and Clinical Thresholds
Line of Therapy Rules
Line of Therapy
Background on Filgrastim
Filgrastim is a granulocyte colony-stimulating factor (G-CSF) used to reduce the incidence of infection manifested by febrile neutropenia in patients receiving myelosuppressive chemotherapy, and for other hematopoietic-support indications described in product labeling and guideline sources.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.